Showing results (181-190 of 438) with videos related to

Sort By:
Pageof 44
International Journal of Molecular Sciences|October 14, 2022
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical ResectionSara Lonardi, Halla Nimeiri, Chang Xu, et al.
The Lancet. Oncology|September 5, 2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE studyChiara Cremolini, Fotios Loupakis, Carlotta Antoniotti, et al.
The Lancet. Oncology|July 24, 2017
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyMichael J Overman, Ray McDermott, Joseph L Leach, et al.
Targeted Oncology|September 7, 2021
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional ExperienceMargherita Rimini, Changhoon Yoo, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2025
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trialsCarlotta Antoniotti, Federica Marmorino, Daniele Rossini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2021
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 StudyHeinz-Josef Lenz, Eric Van Cutsem, Maria Luisa Limon, et al.
European Journal of Cancer (Oxford, England : 1990)|April 18, 2022
Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case seriesEmilie Hafliger, Alessandra Boccaccino, Alexandra Lapeyre-Prost, et al.
Clinical Colorectal Cancer|April 3, 2018
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With RegorafenibMitsukuni Suenaga, Marta Schirripa, Shu Cao, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitorsFrancesca Corti, Sara Lonardi, Rossana Intini, et al.
The Oncologist|July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal CancerRoberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
Pageof 44